Literature DB >> 10021450

Status of gene therapy for cystic fibrosis lung disease.

R C Boucher1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10021450      PMCID： PMC408111          DOI： 10.1172/JCI6330

Source DB:  PubMed          Journal:  J Clin Invest        ISSN： 0021-9738            Impact factor:   14.808


× No keyword cloud information.
  21 in total

1.  Administration of an adenovirus containing the human CFTR cDNA to the respiratory tract of individuals with cystic fibrosis.

Authors:  R G Crystal; N G McElvaney; M A Rosenfeld; C S Chu; A Mastrangeli; J G Hay; S L Brody; H A Jaffe; N T Eissa; C Danel
Journal:  Nat Genet       Date:  1994-09       Impact factor: 38.330

2.  The decline and fall of pulmonary function in cystic fibrosis: new models, new lessons.

Authors:  P B Davis
Journal:  J Pediatr       Date:  1997-12       Impact factor: 4.406

Review 3.  Cystic fibrosis.

Authors:  P B Davis; M Drumm; M W Konstan
Journal:  Am J Respir Crit Care Med       Date:  1996-11       Impact factor: 21.405

4.  Lentiviral vectors for gene therapy of cystic fibrosis.

Authors:  M J Goldman; P S Lee; J S Yang; J M Wilson
Journal:  Hum Gene Ther       Date:  1997-12-10       Impact factor: 5.695

5.  Membrane-associated heparan sulfate proteoglycan is a receptor for adeno-associated virus type 2 virions.

Authors:  C Summerford; R J Samulski
Journal:  J Virol       Date:  1998-02       Impact factor: 5.103

6.  A controlled study of adenoviral-vector-mediated gene transfer in the nasal epithelium of patients with cystic fibrosis.

Authors:  M R Knowles; K W Hohneker; Z Zhou; J C Olsen; T L Noah; P C Hu; M W Leigh; J F Engelhardt; L J Edwards; K R Jones
Journal:  N Engl J Med       Date:  1995-09-28       Impact factor: 91.245

7.  Limited entry of adenovirus vectors into well-differentiated airway epithelium is responsible for inefficient gene transfer.

Authors:  R J Pickles; D McCarty; H Matsui; P J Hart; S H Randell; R C Boucher
Journal:  J Virol       Date:  1998-07       Impact factor: 5.103

8.  Enhanced in vivo airway gene transfer via transient modification of host barrier properties with a surface-active agent.

Authors:  D W Parsons; B R Grubb; L G Johnson; R C Boucher
Journal:  Hum Gene Ther       Date:  1998-12-10       Impact factor: 5.695

9.  In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector.

Authors:  L Naldini; U Blömer; P Gallay; D Ory; R Mulligan; F H Gage; I M Verma; D Trono
Journal:  Science       Date:  1996-04-12       Impact factor: 47.728

10.  Repeat administration of an adenovirus vector encoding cystic fibrosis transmembrane conductance regulator to the nasal epithelium of patients with cystic fibrosis.

Authors:  J Zabner; B W Ramsey; D P Meeker; M L Aitken; R P Balfour; R L Gibson; J Launspach; R A Moscicki; S M Richards; T A Standaert
Journal:  J Clin Invest       Date:  1996-03-15       Impact factor: 14.808
View more
  19 in total

1.  Retargeting the coxsackievirus and adenovirus receptor to the apical surface of polarized epithelial cells reveals the glycocalyx as a barrier to adenovirus-mediated gene transfer.

Authors:  R J Pickles; J A Fahrner; J M Petrella; R C Boucher; J M Bergelson
Journal:  J Virol       Date:  2000-07       Impact factor: 5.103

2.  New insights into the pathogenesis of intestinal dysfunction: secretory diarrhea and cystic fibrosis.

Authors:  Kim E Barrett
Journal:  World J Gastroenterol       Date:  2000-08       Impact factor: 5.742

3.  Comparative genomic sequence analysis of the human and mouse cystic fibrosis transmembrane conductance regulator genes.

Authors:  R E Ellsworth; D C Jamison; J W Touchman; S L Chissoe; V V Braden Maduro; G G Bouffard; N L Dietrich; S M Beckstrom-Sternberg; L M Iyer; L A Weintraub; M Cotton; L Courtney; J Edwards; R Maupin; P Ozersky; T Rohlfing; P Wohldmann; T Miner; K Kemp; J Kramer; I Korf; K Pepin; L Antonacci-Fulton; R S Fulton; P Minx; L W Hillier; R K Wilson; R H Waterston; W Miller; E D Green
Journal:  Proc Natl Acad Sci U S A       Date:  2000-02-01       Impact factor: 11.205

Review 4.  Gene therapy: light is finally in the tunnel.

Authors:  Huibi Cao; Robert S Molday; Jim Hu
Journal:  Protein Cell       Date:  2012-01-10       Impact factor: 14.870

5.  Transient gene transfer and expression of Smad7 prevents bleomycin-induced lung fibrosis in mice.

Authors:  A Nakao; M Fujii; R Matsumura; K Kumano; Y Saito; K Miyazono; I Iwamoto
Journal:  J Clin Invest       Date:  1999-07       Impact factor: 14.808

Review 6.  Gene therapy of cystic fibrosis (CF) airways: a review emphasizing targeting with lactose.

Authors:  D T Klink; M C Glick; T F Scanlin
Journal:  Glycoconj J       Date:  2001-09       Impact factor: 2.916

Review 7.  Gene therapy of cystic fibrosis: the glycofection approach.

Authors:  I Fajac; P Briand; M Monsigny
Journal:  Glycoconj J       Date:  2001-09       Impact factor: 2.916

Review 8.  Vectors for airway gene delivery.

Authors:  Pamela B Davis; Mark J Cooper
Journal:  AAPS J       Date:  2007-01-19       Impact factor: 4.009

Review 9.  Pseudomonas aeruginosa infection in cystic fibrosis lung disease and new perspectives of treatment: a review.

Authors:  M C Gaspar; W Couet; J-C Olivier; A A C C Pais; J J S Sousa
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2013-04-26       Impact factor: 3.267

10.  Protection of Cftr knockout mice from acute lung infection by a helper-dependent adenoviral vector expressing Cftr in airway epithelia.

Authors:  David R Koehler; Umadevi Sajjan; Yu-Hua Chow; Bernard Martin; Geraldine Kent; A Keith Tanswell; Colin McKerlie; Janet F Forstner; Jim Hu
Journal:  Proc Natl Acad Sci U S A       Date:  2003-12-12       Impact factor: 11.205
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.